Belsomra Cost in Montana 2026: Suvorexant Prices, Insurance, and Compounding Options

What Is Suvorexant (Belsomra) and How Does It Work?

Suvorexant is a dual orexin receptor antagonist (DORA) approved by the FDA in August 2014 for adults with insomnia characterized by difficulty with sleep onset or maintenance. Unlike older sedative-hypnotics that broadly depress the central nervous system, suvorexant blocks the binding of orexin-A and orexin-B neuropeptides at OX1R and OX2R receptors, quieting the arousal signal that keeps patients awake. The FDA prescribing information classifies it as a Schedule IV controlled substance under the Controlled Substances Act.

Clinical Evidence Supporting Suvorexant

The key registration program was reported by Herring et al. In a pooled analysis of two phase-3 trials published in The Lancet Neurology in 2014 (N = 1,021 in trial 1; N = 1,019 in trial 2). Suvorexant 20 mg reduced subjective sleep-onset latency by a mean of 9 to 28 minutes versus placebo across both trials, and improved wake after sleep onset by 16 to 28 minutes [1]. The effect was detectable from night one.

A separate randomized trial by Herring et al. In older adults (mean age 71.1 years, N = 312) found suvorexant 15 mg and 30 mg (doses later revised downward by the FDA) produced statistically significant reductions in wake time compared with placebo (P<0.001) [2]. The FDA's clinical pharmacology review notes that maximum plasma concentration is reached within two hours and that a high-fat meal delays absorption by approximately 1.5 hours.

Safety Profile in Brief

The most common adverse event in trials was somnolence, reported in 7% of patients on suvorexant 20 mg versus 3% on placebo [1]. Sleep paralysis, hypnagogic or hypnopompic hallucinations, and cataplexy-like symptoms occurred in <1% of participants. The American Academy of Sleep Medicine (AASM) clinical practice guideline recommends suvorexant as a treatment option for chronic insomnia disorder, citing a favorable evidence base from randomized controlled trials.

A 2023 Cochrane review of pharmacological interventions for insomnia (Brasure et al.) confirmed that DORAs including suvorexant produce clinically meaningful improvements in sleep outcomes with a tolerability profile preferable to benzodiazepines and Z-drugs [3].

Belsomra Cash Price in Montana in 2026

Retail Pharmacy Pricing

The average cash-pay price for branded Belsomra at Montana retail pharmacies in 2026 is approximately $85 per month for a 30-tablet supply, well below Merck's wholesale list price of $340 per month. The gap exists because major pharmacy benefit managers and discount-card platforms (GoodRx, RxSaver, Cost Plus Drugs) negotiate prices that have no connection to the manufacturer's suggested retail. Prices vary by 10% to 20% across cities such as Billings, Missoula, Great Falls, and Bozeman.

Generic suvorexant became available in the United States after Merck's composition-of-matter patents expired, and some Montana pharmacies dispense it for $40 to $60 per month on discount cards. Confirm availability with your specific pharmacy before writing the prescription as "brand medically necessary" versus "dispense as written," because generic substitution dramatically changes out-of-pocket cost.

Dose-by-Dose Price Breakdown

The FDA-approved dosing range for suvorexant is 5 mg to 20 mg taken once at bedtime. Prescribers often start at 10 mg. Higher doses do not uniformly cost more at retail because pack sizes are fixed at 30 tablets per month regardless of strength. However, the 20 mg tablet may be priced 5% to 8% above the 10 mg tablet at some Montana chains.

A 2022 JAMA Health Forum analysis of sleep aid spending in the United States found that out-of-pocket costs for brand-name sleep medications were the primary driver of non-adherence, with patients citing cost as a barrier more frequently than side effects. Montana residents face additional barriers because the state has fewer retail pharmacy locations per capita than national medians, and rural zip codes (e.g., Phillips County) may have only one dispensing option within 60 miles.

Does Montana Medicaid Cover Belsomra?

Montana Medicaid does not cover Belsomra (suvorexant) as of 2026. The Montana Department of Public Health and Human Services Preferred Drug List (PDL) does not include suvorexant on its formulary for the Medicaid fee-for-service program. This means Medicaid beneficiaries pay full cash price unless they obtain a prior authorization (PA) exception.

Prior Authorization Exceptions

Medicaid PA exceptions for non-formulary drugs in Montana require documentation that at least two formulary alternatives failed or are contraindicated. For insomnia, the formulary alternatives typically include trazodone (50 mg to 100 mg) and hydroxyzine. The PA process may take five to ten business days. The Montana Medicaid Pharmacy Program publishes the current PDL and PA request forms on its official portal.

The Centers for Medicare and Medicaid Services (CMS) notes that states retain formulary discretion for most non-preferred brand drugs, which is why coverage for the same medication can differ dramatically across state Medicaid programs. If PA is denied, patients may appeal through the Montana Medicaid grievance and appeals process, which has a statutory resolution deadline of 30 days for standard reviews.

Medicare Part D in Montana

Medicare Part D plans operating in Montana vary in their coverage of suvorexant. In 2025 and 2026, several Part D plans placed generic suvorexant on Tier 2 (preferred generic) with a copay of $5 to $20 per month after the deductible. Branded Belsomra, if covered at all, sits on Tier 4 or Tier 5 in most Montana Part D formularies, producing a copay of $80 to $130 per month. The Medicare Plan Finder tool allows beneficiaries to compare specific plan coverage by zip code and drug name.

Commercial Insurance Coverage for Belsomra in Montana

Most commercial insurance plans sold in Montana cover suvorexant at Tier 3 (non-preferred brand) or Tier 2 (preferred brand, if generic suvorexant is preferred). Typical patient cost-sharing after deductible ranges from $30 to $80 per month depending on plan design.

Step Therapy Requirements

Many Montana insurers require step therapy before approving suvorexant. Step therapy protocols typically mandate a trial of one or two lower-cost generic sleep aids (most commonly trazodone or a benzodiazepine receptor agonist such as zolpidem) before suvorexant is covered. The American Academy of Sleep Medicine's position statement on step therapy argues that step therapy requirements for chronic insomnia can delay appropriate care, particularly when a DORA is clinically preferred due to comorbidities such as respiratory disease or a history of substance use disorder.

Montana House Bill 221 (enacted 2021) requires Montana insurers to allow step therapy overrides when a prescriber documents clinical justification. Prescribers can submit a step therapy exception request directly to the insurer, and plans must respond within 72 hours for urgent requests or 30 days for standard requests.

Using an Employer-Sponsored Plan

If you receive insurance through a Montana employer, coverage terms follow the employer's plan document, not Montana's individual-market regulations. Self-insured employer plans (governed by ERISA) are exempt from Montana's step therapy override law. Check your Summary of Benefits and Coverage (SBC) or call your plan's pharmacy benefits manager (PBM) directly to confirm suvorexant's tier status.

Compounded Suvorexant in Montana: Legality and Cost

503A Pharmacy Rules

Compounded suvorexant is legally available in Montana through 503A compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to prepare compounds for individual patients based on a valid prescription from a licensed practitioner. Montana's Board of Pharmacy enforces these rules in alignment with federal law. The FDA's guidance on 503A compounding distinguishes patient-specific 503A compounds from large-scale 503B outsourcing-facility production.

Suvorexant is not currently on the FDA's list of bulk drug substances that cannot be compounded. A licensed prescriber in Montana can write a prescription for compounded suvorexant specifying a custom dose form (e.g., an oral capsule at 12 mg) that a 503A pharmacy then prepares. The compound is filled under the patient's name and cannot be dispensed without a valid prescription.

Cost of Compounded Suvorexant

Compounded suvorexant from a 503A pharmacy in Montana typically costs $0 to $30 per month out-of-pocket when prescribed through a telehealth practice that has an affiliated compounding pharmacy relationship. Some telehealth platforms include the cost of the compound in a monthly membership fee, effectively reducing the drug cost to $0 at the point of dispensing. This is the primary mechanism by which Montana patients currently access suvorexant at the lowest possible cost.

Commercial insurance generally does not cover compounded medications. Medicaid does not cover compounded suvorexant in Montana.

Quality Considerations for Compounded Suvorexant

The FDA has not evaluated compounded suvorexant for safety, efficacy, or potency in the same way it reviewed Belsomra during the NDA process. Patients and prescribers should verify that the compounding pharmacy is licensed by Montana's Board of Pharmacy, operates under current Good Compounding Practices, and performs third-party potency and sterility testing. The FDA's MedWatch reporting system allows patients and providers to report adverse events from compounded products.

A 2020 JAMA study examining compounded drug quality found that 9% of sampled compounded products failed potency or sterility standards, underscoring the importance of pharmacy vetting before dispensing.

The Merck Savings Card and Patient Assistance in Montana

How the Merck Savings Card Works

Merck offers a savings card for Belsomra that reduces cost-sharing for commercially insured patients. Eligible patients pay as little as $30 for a 30-day supply, with Merck covering the balance up to a defined monthly cap. The card is not valid for patients covered by federal or state government programs, including Medicare, Medicaid, TRICARE, or the VA. Montana residents enrolled in these programs cannot use the Merck savings card.

To enroll, a patient must have a valid commercial insurance plan, reside in the United States, and not be enrolled in any government-funded health program. The savings card is activated at the pharmacy counter and generally works with any retail pharmacy in Montana that accepts Merck's third-party processor. Merck's patient assistance line for eligibility questions is listed on Merck's official prescriber resources page.

Merck Patient Assistance Program

For patients who are uninsured and meet income criteria (typically household income at or below 400% of the federal poverty level), Merck's Patient Assistance Program (PAP) may supply Belsomra at no cost. Applications require proof of income, a prescriber attestation, and documentation of insurance status. Processing takes four to six weeks on average. Montana residents can apply through NeedyMeds or directly through Merck's assistance portal.

Getting Belsomra or Suvorexant via Telehealth in Montana

Telehealth prescribing of suvorexant is permitted in Montana under the state's telehealth practice laws. Montana Code Annotated Title 37 allows licensed practitioners to prescribe Schedule IV controlled substances via synchronous audiovisual telehealth after conducting a clinically appropriate evaluation. A Montana-licensed prescriber must authorize the prescription; out-of-state prescribers not licensed in Montana cannot prescribe controlled substances to Montana residents.

The Drug Enforcement Administration's (DEA) telemedicine rules for Schedule IV substances require at minimum a synchronous audio-visual encounter. Text-only or asynchronous telehealth is not sufficient for a suvorexant prescription under federal DEA rules.

Most Montana-serving telehealth platforms complete the initial consultation within 24 to 48 hours. Once a prescription is issued, it can be sent electronically to any licensed Montana retail pharmacy or to an affiliated 503A compounding pharmacy. Refills require a follow-up prescription; Schedule IV substances in Montana may be refilled up to five times within six months of the original prescription date under DEA regulations, as outlined in 21 CFR 1306.22.

Dosing Reference for Montana Prescribers and Patients

Suvorexant is taken once per night, immediately before bed, with at least seven hours remaining before the planned wake time. The FDA-approved label recommends starting at 10 mg and increasing to 20 mg if tolerated and clinically needed. The 5 mg dose may be used in patients on moderate CYP3A4 inhibitors. Doses above 20 mg are not recommended.

A 2019 randomized trial by Sun et al. Comparing suvorexant 10 mg with placebo in 291 patients with Alzheimer's disease-related insomnia found that suvorexant reduced nighttime wake time by 35.0 minutes versus 22.5 minutes with placebo (P<0.05), representing a clinically meaningful difference in this high-need population.

The American Geriatrics Society Beers Criteria (2023) no longer lists suvorexant as a potentially inappropriate medication in older adults, a departure from older sedative-hypnotics such as zolpidem and temazepam, which remain on the list. This is a clinically useful point for Montana prescribers treating older patients in long-term care or assisted living facilities.

Comparing Suvorexant to Other Sleep Medications Available in Montana

| Medication | Class | Typical Montana Cash Price (2026) | MT Medicaid Covered | Schedule | |---|---|---|---|---| | Suvorexant (generic) | DORA | $40-$60/mo | No | IV | | Belsomra (brand) | DORA | ~$85/mo | No | IV | | Lemborexant (Dayvigo) | DORA | ~$280/mo | No | IV | | Zolpidem (generic) | Z-drug | $5-$15/mo | Yes | IV | | Trazodone (generic) | SARI | $4-$10/mo | Yes | Unscheduled | | Doxepin 3-6 mg (Silenor) | TCA | $80-$120/mo | No | Unscheduled |

Zolpidem and trazodone remain the most cost-accessible options for Montana Medicaid beneficiaries. Suvorexant and lemborexant offer mechanistic advantages for patients with respiratory comorbidities or substance use history because DORAs do not cause respiratory depression at therapeutic doses, a property confirmed in a 2020 review published in Sleep Medicine Reviews.